Site-specific radiolabeling of an anti-HER2 single domain antibody fragment with an 211At-labeled prosthetic agent: preliminary evaluation of a potential targeted α-particle therapeutic
Publication
, Conference
Feng, Y; Sarrett, S; Meshaw, R; Vaidyanathan, G; Zeglis, B; Zalutsky, M
Published in: NUCLEAR MEDICINE AND BIOLOGY
2022
Duke Scholars
Published In
NUCLEAR MEDICINE AND BIOLOGY
EISSN
1872-9614
ISSN
0969-8051
Publication Date
2022
Volume
108
Start / End Page
S32 / S32
Related Subject Headings
- Nuclear Medicine & Medical Imaging
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Feng, Y., Sarrett, S., Meshaw, R., Vaidyanathan, G., Zeglis, B., & Zalutsky, M. (2022). Site-specific radiolabeling of an anti-HER2 single domain antibody fragment with an 211At-labeled prosthetic agent: preliminary evaluation of a potential targeted α-particle therapeutic. In NUCLEAR MEDICINE AND BIOLOGY (Vol. 108, pp. S32–S32).
Feng, Yutian, Samantha Sarrett, Rebecca Meshaw, Ganesan Vaidyanathan, Brian Zeglis, and Michael Zalutsky. “Site-specific radiolabeling of an anti-HER2 single domain antibody fragment with an 211At-labeled prosthetic agent: preliminary evaluation of a potential targeted α-particle therapeutic.” In NUCLEAR MEDICINE AND BIOLOGY, 108:S32–S32, 2022.
Feng Y, Sarrett S, Meshaw R, Vaidyanathan G, Zeglis B, Zalutsky M. Site-specific radiolabeling of an anti-HER2 single domain antibody fragment with an 211At-labeled prosthetic agent: preliminary evaluation of a potential targeted α-particle therapeutic. In: NUCLEAR MEDICINE AND BIOLOGY. 2022. p. S32–S32.
Feng, Yutian, et al. “Site-specific radiolabeling of an anti-HER2 single domain antibody fragment with an 211At-labeled prosthetic agent: preliminary evaluation of a potential targeted α-particle therapeutic.” NUCLEAR MEDICINE AND BIOLOGY, vol. 108, 2022, pp. S32–S32.
Feng Y, Sarrett S, Meshaw R, Vaidyanathan G, Zeglis B, Zalutsky M. Site-specific radiolabeling of an anti-HER2 single domain antibody fragment with an 211At-labeled prosthetic agent: preliminary evaluation of a potential targeted α-particle therapeutic. NUCLEAR MEDICINE AND BIOLOGY. 2022. p. S32–S32.
Published In
NUCLEAR MEDICINE AND BIOLOGY
EISSN
1872-9614
ISSN
0969-8051
Publication Date
2022
Volume
108
Start / End Page
S32 / S32
Related Subject Headings
- Nuclear Medicine & Medical Imaging
- 3202 Clinical sciences
- 1103 Clinical Sciences